Alexion Pharmaceuticals
ALXN
ALXN was delisted on the 20th of July, 2021.
584 hedge funds and large institutions have $29.5B invested in Alexion Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 59 funds opening new positions, 215 increasing their positions, 211 reducing their positions, and 69 closing their positions.
13% more capital invested
Capital invested by funds: $26.2B → $29.5B (+$3.35B)
6% more funds holding in top 10
Funds holding in top 10: 17 → 18 (+1)
2% more repeat investments, than reductions
Existing positions increased: 215 | Existing positions reduced: 211
0% more call options, than puts
Call options by funds: $257M | Put options by funds: $256M
3% less funds holding
Funds holding: 600 → 584 (-16)
14% less first-time investments, than exits
New positions opened: 59 | Existing positions closed: 69
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
+$326M |
| 2 |
JP Morgan Chase
New York
|
+$265M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$198M |
| 4 |
American Century Companies
Kansas City,
Missouri
|
+$148M |
| 5 |
IAM
Iridian Asset Management
Westport,
Connecticut
|
+$109M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$148M |
| 2 |
CLM
ClearBridge LLC (Maryland)
Baltimore,
Maryland
|
-$89M |
| 3 |
PC
PointState Capital
New York
|
-$87.9M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$87.1M |
| 5 |
MWNA
Marshall Wace North America
New York
|
-$76M |
ALXN Hedge Fund Activity: Q3 2018 in Review
584 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Alexion Pharmaceuticals (ALXN) for Q3 2018, worth a combined $29.5B — up 13% from $26.2B a quarter earlier.
Sellers outnumbered buyers: 69 funds closed out of ALXN and 59 opened new positions — a net loss of 10 holders — while 211 trimmed existing stakes and 215 added.
The largest buyer was Jennison Associates, adding an estimated $326M. The largest seller was T. Rowe Price Associates, cutting an estimated $148M.
- 584 institutional investors held Alexion Pharmaceuticals (ALXN) as of Q3 2018, down from 600 in Q2 2018.
- Funds reported $29.5B of Alexion Pharmaceuticals stock for Q3 2018, up 13% quarter-over-quarter.
- 59 funds opened new Alexion Pharmaceuticals positions in Q3 2018 and 69 closed out, a net change of -10 holders.
- The largest Alexion Pharmaceuticals buyer in Q3 2018 was Jennison Associates, an estimated $326M added.
- The largest Alexion Pharmaceuticals seller in Q3 2018 was T. Rowe Price Associates, an estimated $148M sold.
Based on aggregated 13F filings for Q3 2018.